TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07861542: A Phase 4 Open-label, Single-arm Study to Evaluate the Safety and Immunogenicity of an Omicron Subvariant-based SARS-CoV-2 Recombinant Spike (rS) Vaccine Adjuvanted With Matrix-M in Participants ≥ 65 Years of Age and Par

Sponsor: Sanofi · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 660 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,832,000

Rescue Site Savings

+$5,823,600

Unlock Full NCT07861542 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07861542 Rescue Dossier →